Obstructive Sleep Apnea (OSA) Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Obstructive Sleep Apnea Drugs Market: By Drugs (CNS stimulants, Benzodiazepines, and Hypnotics), By Distribution channel (Hospital pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Obstructive Sleep Apnea Drugs Market size was valued at USD 9,153.7 million in 2021, growing at a CAGR of 3.7% from 2022-2028. Sleep apnea is a sleeping disease caused by irregular breathing and oxygen deprivation of the brain. According to a study published in 2020 by the American Sleep Association, between 50 and 70 million people in the United States suffer from sleep disorders. According to research published by the American Sleep Association in 2020, an estimated 50 million to 70 million persons in the United States suffer from sleep disturbances. Furthermore, the Canadian Respiratory Journal reported in 2014 that around 5.4 million persons in Canada had been diagnosed with sleep apnea or were at risk of acquiring Obstructive sleep apnea. A surge in the prevalence of sleep apnea is majorly driving the growth of the sleep apnea treatment market. Furthermore, the growing geriatric population, rising lifestyle changes, growing home care acceptance coupled with the awareness of sleep disorders, improving healthcare infrastructure, an introduction of new technologies, and innovative products are expected to fuel the growth of the sleep apnea treatment market. The massive pool of undiagnosed patients with sleep apnea holds tremendous potential for the sleep apnea devices market. The older population has a significant prevalence of sleep apnea, which is underdiagnosed due to lack of knowledge and the disease’s non-specific presentation. Sleep disturbances are projected to become more common as the senior population grows as life expectancy increases. According to the WHO, the global population of persons aged 60 and more is predicted to reach 2.0 billion by 2050 in 2018. Because this population group is more susceptible to sleep apnea, an increase in the senior population is projected to enhance the use of these devices. Furthermore, because comorbidities linked with sleep apnea are high among the elderly, the prevalence of sleep apnea is rising in the geriatric population.

Recent Market Developments:

In May 2022, Axsome Therapeutics, Inc. a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced the completion of its U.S. acquisition of Sunosifrom Jazz Pharmaceuticals. Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). The ex-U.S. transaction is expected to close within 60 days.

In March 2020, Clearmind Medicine Inc, a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced a Collaboration agreement (with SciSparc Ltd. The Collaboration will address, inter alia, examining the benefit of integrating the core technologies of each company by combining molecules from their respective development pipelines.

Obstructive Sleep Apnea (OSA) Drugs Market

MARKET SUMMARY
-
3.7%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 3.7%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Obstructive Sleep Apnea (OSA) Drugs Market

  • The report on global Obstructive Sleep Apnea (OSA) Drugs Market gives historical, current, and future market sizes (US$ Mn) on the basis of drugs, distribution channel and geography.
  • Obstructive Sleep Apnea (OSA) Drugs Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Biogen, Inc
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Eli Lilly & Company
Obstructive Sleep Apnea (OSA) Drugs Market Dynamics

The enormous pool of undiagnosed sleep apnea patients, growing knowledge about the adverse effects of untreated sleep apnea, and an increasing number of players venturing into the sleep apnea industry are driving market expansion. With the ongoing awareness campaigns and efforts, it is envisaged that a new patient base will be diagnosed and treated for sleep apnea. However, the sleep apnea treatment market is projected to be hampered by tight regulatory procedures, pharmacological side effects, and intense market rivalry.


North-America Got Significant Share

Obstructive Sleep Apnea (OSA) Drugs Market

The enormous pool of undiagnosed sleep apnea patients, growing knowledge about the adverse effects of untreated sleep apnea, increasing use of oral appliances, and an increasing number of players venturing into the sleep apnea industry are driving market expansion. With the ongoing awareness campaigns and efforts, it is envisaged that a new patient base will be diagnosed and treated for sleep apnea. However, the sleep apnea treatment market is hampered by tight regulatory procedures, pharmacological side effects, and intense market rivalry.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, and forecast
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Obstructive Sleep Apnea (OSA) Drugs Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Biogen, Inc (U.S).
  • Pfizer, Inc. (U.s)
  • Johnson & Johnson Services, Inc. (U.S)
  • Otsuka America Pharmaceutical, Inc. (U.S)
  • Eli Lilly & Company (U.S)
  • Merck & Co., Inc. (U.S)
  • AstraZeneca (UK)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Shire Plc. (Ireland)

Description

Obstructive Sleep Apnea Drugs Market size was valued at USD 9,153.7 million in 2021, growing at a CAGR of 3.7% from 2022-2028. Sleep apnea is a sleeping disease caused by irregular breathing and oxygen deprivation of the brain. According to a study published in 2020 by the American Sleep Association, between 50 and 70 million people in the United States suffer from sleep disorders. According to research published by the American Sleep Association in 2020, an estimated 50 million to 70 million persons in the United States suffer from sleep disturbances. Furthermore, the Canadian Respiratory Journal reported in 2014 that around 5.4 million persons in Canada had been diagnosed with sleep apnea or were at risk of acquiring Obstructive sleep apnea. A surge in the prevalence of sleep apnea is majorly driving the growth of the sleep apnea treatment market. Furthermore, the growing geriatric population, rising lifestyle changes, growing home care acceptance coupled with the awareness of sleep disorders, improving healthcare infrastructure, an introduction of new technologies, and innovative products are expected to fuel the growth of the sleep apnea treatment market. The massive pool of undiagnosed patients with sleep apnea holds tremendous potential for the sleep apnea devices market. The older population has a significant prevalence of sleep apnea, which is underdiagnosed due to lack of knowledge and the disease’s non-specific presentation. Sleep disturbances are projected to become more common as the senior population grows as life expectancy increases. According to the WHO, the global population of persons aged 60 and more is predicted to reach 2.0 billion by 2050 in 2018. Because this population group is more susceptible to sleep apnea, an increase in the senior population is projected to enhance the use of these devices. Furthermore, because comorbidities linked with sleep apnea are high among the elderly, the prevalence of sleep apnea is rising in the geriatric population.

Recent Market Developments:

In May 2022, Axsome Therapeutics, Inc. a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced the completion of its U.S. acquisition of Sunosifrom Jazz Pharmaceuticals. Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). The ex-U.S. transaction is expected to close within 60 days.

In March 2020, Clearmind Medicine Inc, a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced a Collaboration agreement (with SciSparc Ltd. The Collaboration will address, inter alia, examining the benefit of integrating the core technologies of each company by combining molecules from their respective development pipelines.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX